Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]-Varlitinib in Healthy Males
NCT03368846Phase 1Completed
- Sponsor
- ASLAN Pharmaceuticals
- Start
- Nov 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of varlitinib in solid tumor, sponsored by ASLAN Pharmaceuticals. Primary endpoints: Mass balance recovery after a single oral dose of [14C] varlitinib at 13 days and Metabolite profiling and structural identification of metabolites in plasma, urine and faeces at 13 days. Started Nov 2017; status: completed.
02
Drugs
varlitinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03368846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03368846.